摘要
目的:评估自体DC与CIK细胞治疗难治复发急性髓细胞白血病的近期疗效与安全性。方法:给予20例难治复发急性髓细胞白血病患者树突状细胞(DC)与细胞因子诱导的杀伤细胞(CIK)治疗,20例难治复发的应用同样化疗方案的急性髓细胞白血病患者做为对照组;治疗后4周观察两组患者临床疗效和生存质量(KPS)评分,DC与CIK细胞治疗前和治疗后1周检测T细胞亚群(CD3+、CD3+CD4+、CD3+CD8+、CD3+CD56+)和细胞因子(IL-12、IL-2、IL-7、IFN-γ及TNF-α)水平的变化。结果:①DC与CIK细胞治疗组有效率和KPS评分明显高于对照组(P<0.05),所有患者的不良反应轻微,均可耐受。②DC与CIK细胞治疗后1周,患者T细胞亚群百分比和细胞因子含量较治疗前均明显升高,其中CD3+、CD3+CD56+及IL-12、IL-7明显升高(P<0.05)。结论:DC与CIK细胞免疫治疗难治复发急性髓细胞白血病安全有效。
Objective： To evaluate the efficacy and safety of autologous DC and CIK cell in the treatment of refractory and recurrent acute myeloid leukemia（AML）. Methods： Combination of autologous DC and CIK cells was used to treat 20 cases of refractory and recurrent patients with acute myeloid leukemia, At the same time, 20 cases of refractory and recurrent patients with AML treated by same plan were set as the control group. Clinical efficacy and Qualicty of life （KPS） were observed after 4 weeks in two group. T cell subsets（CD3＋, CD3＋CD4＋, CD3＋CD8＋, CD3＋CD56＋） and Cytokine （IL-12, IL-2, IL-7, IFN-γand TNF-α） were detected after 4 weeks and before treatment with DC and CIK. Results： （L）The effective rate and KPS in refractory and recurrent patients with AML were significantly higher than those of the control group （P 〈0.05）. All patients with adverse reactions were mild and tolerable. （1）After 4 weeks＇ treatment with DC and CIK, the percentage of T cell subsets （CD3 ＋,CD3＋CD4＋, CD3＋CD8＋ and CD3＋ CD56＋） and Cytokine （IL-12, IL-2, IL-7, IFN-γ and TNF-α were improved than before treatment, CD3＋, CD3＋CD56＋ and IL-12, IL-γ improved significantly （P 〈0.05）. Conclusion： DC and CIK cell immunotherapy was a safe and efficacious therapeutic measure in the treatment of refractory and recurrent adult patients with AML.
出处
《现代生物医学进展》
CAS
2014年第1期159-162,共4页
Progress in Modern Biomedicine
基金
黑龙江省科技厅课题(QC2012C050)
